Careers
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, a first-in-class intranasal antiviral designed to provide broad protection against respiratory viruses at the point of entry. Our simple, preventative approach was evaluated in a Phase 2 human influenza challenge study, demonstrating reduced symptomatic influenza compared with placebo, with comparable safety and tolerability to placebo.